The Patient Protection and Affordable Care Act is expected to reduce the number of uninsured people in the United States during the next eight years, but more than 10% are expected to remain uninsured. Uninsured people are one of the main populations using publicly funded safety net sexually transmitted disease (STD) prevention services. Estimating the proportion of the uninsured population expected to need STD services could help identify the potential demand for safety net STD services and improve program planning. In 2013, an estimated 8.27 million people met the criteria for being in need of STD services. In 2023, 4.70 million uninsured people are expected to meet the criteria for being in need of STD services. As an example, the cost in 2014 U.S. dollars of providing chlamydia screening to these people was an estimated $271.1 million in 2013 and is estimated to be $153.8 million in 2023. A substantial need will continue to exist for safety net STD prevention services in coming years.
The Patient Protection and Affordable Care Act is expected to increase the number of people in the United States with health insurance during the next eight years, 1 partly by expanding access to Medicaid 2 and creating health insurance marketplaces. 3 However, insurance coverage is not expected to reach 100% of the population. 1 Although the Affordable Care Act provides premium subsidies for those who are at 400% of the federal poverty level 4 and allows for dependent coverage up to 26 years of age, 5 some factors that have limited insurance coverage in the past will still be present, to some degree. For example, cost may be a barrier, even with subsidies. A 2009 survey found that 48% of those who are uninsured cited cost as a reason for not having health coverage. 6 People who are uninsured and have to pay for their care may be more likely to seek low-or no-cost options for care.
Studies have shown that patients who seek care at sexually transmitted disease (STD) clinics have lower incomes than the general population, are less likely to have health insurance, and have cited low cost of care as an important reason for presenting to STD clinics. [7] [8] [9] Furthermore, cost has been cited as an important reason for choosing care at STD clinics, and the imposition of fees or copays has been shown to reduce the number of patient visits. 8, 10, 11 Surveys have shown that many STD clinic patients have insurance, but some STD clinic patients with insurance have reported that they would not be willing to use their insurance due to confidentiality concerns. 8, 9 From 2002 to 2006-2010, receipt of STD services among U.S. women increased among most subpopulations, with the exception of uninsured women. 12 These factors suggest that low-or no-cost STD care may continue to be important for people lacking health insurance or with limited coverage.
STDs such as chlamydia are common, 13 and the U.S. Preventive Services Task Force recommends that sexually active women aged #24 years be screened annually for chlamydia. 14 The Centers for Disease Control and Prevention (CDC) additionally recommends chlamydia screening for all pregnant women regardless of age, annually for men who have sex with men, and for people newly diagnosed with human immunodeficiency virus infection. 15 Although there are no other guidelines for chlamydia screening in men, having multiple sex partners is a risk factor for infection and repeat infection. [15] [16] [17] For both men and women diagnosed with chlamydia, CDC recommends repeat screening three months after treatment. 15 Given the changes in the health-care landscape in the United States, we estimated the size of the uninsured population aged 15-44 years in need of STD services based on existing clinical guidelines or elevated STD risk. To estimate a lower bound of the cost of providing STD services to the population in need of services, we estimated the annual cost of chlamydia screening, diagnostic testing, treatment, and repeat testing from 2013-2023 according to CDC guidelines.
METHODS
To estimate the size of the uninsured population, we used data from the U.S. Census, Congressional Budget Office (CBO), and the National Survey of Family Growth (NSFG), a nationally representative survey of the reproductive-aged population, which is described elsewhere. 18 The CBO has produced estimates of the percentage of the non-elderly population who will be uninsured for each year through 2023. 1, 19 Data on the U.S. population aged 15-44 years came from the 2010 U.S. Census and Census projections for the years 2015, 2020, and 2025. 20, 21 We used straight-line extrapolation for years between the published estimates and apportioned population growth among racial/ethnic groups equal to their current proportions of the population (Technical Appendix).
To calculate the size of the population that is expected to need STD services and to estimate chlamydia prevalence, we used data from the NSFG 18 and the National Health and Nutrition Examination Survey (NHANES). 22 Data on self-reported pregnancy status, number and sex of sex partners in the last 12 months, and insurance status by age group and race/ethnicity were taken from the NSFG. Data from 2006-2010 were combined into a single sample to increase the sample size and enable age, race/ethnicity, and sex-stratified analysis. People in the population expected to need STD services were defined as women aged 15-24 years with $1 sex partner in the last 12 months or aged 25-44 years with .1 sex partner in the last 12 months or pregnant, or men with $1 male sex partner or .1 sex partner in the last 12 months. Data on chlamydia prevalence by age group and race/ethnicity were taken from NHANES. We analyzed chlamydia prevalence data from NHANES for those aged 15-39 years; these data were grouped into two age categories: 15-24 and 25-44 years. For cost analysis purposes, the chlamydia prevalence for people aged 40-44 years was assumed to be the same as for people aged 25-39 years. High relative standard errors and small cell sizes prevented including insurance status for subgroup analysis of chlamydia prevalence. Data for the years 1999-2010 were combined into a single sample for the subgroup analyses.
Estimates were taken from the literature for the cost of providing chlamydia screening, diagnostic testing, repeat testing, and treatment services from the cost perspective of local or state health departments. 23, 24 Sequelae and patient time and travel costs were not included. All costs were adjusted to 2014 U.S. dollars using the Medical Care component of the Consumer Price Index (Technical Appendix). 25 
RESULTS
The percentage uninsured and in need of services varied by age group, sex, and race/ethnicity (Table 1) . The number of uninsured men and women needing STD services was estimated to be 8.27 million in 2013 , and remaining essentially unchanged through 2023. The cost of providing chlamydia screening, diagnostic testing, and treatment to this population is expected to decline from $271.1 million in 2013 to $150.3 million in 2016, and then increase thereafter due to population growth.
DISCUSSION
Our estimates suggest that a substantial need for safety net STD services for uninsured people will remain through 2023. Access to STD services is important for reducing morbidity and for population health. 15 The percentages of people who are uninsured and need STD services are relatively higher in racial/ethnic groups that bear a disproportionate STD burden, including non-Hispanic black and Hispanic people. 13 The cost estimates focused on chlamydia screening alone because more cases of chlamydia are reported than gonorrhea or syphilis, and the recommendations for chlamydia screening are well established. [13] [14] [15] The total cost of providing STD prevention services to uninsured people in need of STD services would be higher than the cost of chlamydia screening because the cost of chlamydia services does not include the cost of providing screening or diagnostic testing for other STDs or the cost of recommended vaccinations. Therefore, the cost of chlamydia screening represents a lower bound, but one that would be applicable to a relatively large proportion of the population. The drop in cost shown during the years 2013-2016 indicates that insurance coverage is expected to increase during that time, but a substantial need for STD services in the uninsured population will remain. Although not all people who need STD services will receive them, providing low-or no-cost STD services with limited or no delay is important in maintaining access, particularly for people lacking regular healthcare providers. 26
Limitations
Our analysis was subject to several limitations. We used several data sources that spanned varying time frames, which could have introduced error. Population growth was assumed to be proportional to the current population, and chlamydia prevalence in those aged 40-44 years was assumed to be the same as that of 25-to 39-year-olds; these assumptions about population growth and chlamydia prevalence in adults aged 40-44 years are simplifications. It was also assumed that chlamydia prevalence would remain the same through 2023. These limitations have a relatively small potential impact on the overall cost estimate, however; chlamydia treatment and repeat screening costs add 10% to the overall costs (e.g., the total costs for 2023 without repeat screening would be an estimated $139.6 million). Another limitation was the scope of this analysis, which focused on those without insurance. Surveys have shown that a demand for safety net STD care exists among patients with insurance. [8] [9] [10] [11] Patients who cannot seek confidential care without using their insurance may be inhibited from seeking care. 9, 11, 26 CONCLUSION Estimates using data from health surveys, the U.S. Census, and the CBO suggest that several million uninsured people aged 15-44 years will be in need of STD services during the next eight years. The substantial cost of providing chlamydia screening services to this population indicates that a role for safety net STD services will continue in coming years.
